Plasma Therapy Market Research Report—Global Forecast till 2030

Plasma Therapy Market: by Type (Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin, and Leukocyte-Rich Fibrin), by Source (Autologous, Allogenic), by Application (Orthopedic, Dermatology, Cardiac Muscle Injury, Dental, Nerve Injury), End Users (Hospitals & Clinics and Research Institutions) and by Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast to 2030

ID: MRFR/HC/9249-HCR | January 2023 | Region: Global | 120 Pages         

Plasma Therapy Market Speak to Analyst Request a Free Sample

Plasma Therapy Market

plasma therapy market is expected to cross ~USD 895.45 million by 2030 at a CAGR of ~13.8%

Segmentation
By Type Pure PRP Leukocyte-Rich PRP Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin
By Source Autologous Allogenic
By Application Orthopedic Dermatology Cardiac Muscle Injury Dental Nerve Injury
End Users Hospitals & Clinics and Research Institutions
Key Players
Companies Profiled   BioLife Plasma Services (US)    Cambryn Biologics LLC (US)    Biotest (Germany)    CSL Ltd. (Australia)    Grifols International S.A. (Spain)    Kedrion S.p.A. (Italy)    LFB S.A (France)    Bio Products Laboratory Ltd. (U.K.)    China Biologic Products
Drivers
Market Driving Forces   Rise in COVID-19 cases around the globe   Rising awareness among the population regarding the diseases and potential treatment options
Request a Free Sample

Plasma Therapy Market Overview

The global plasma therapy market is expected to cross USD 895.45 million by 2030 at a CAGR of 13.8%. Plasma therapy can replace missing or deficient proteins that allow individuals to lead healthy and disorder-free lives. Due to increasing plasma-fractionation techniques, human blood produces several plasma-derived therapies for debilitating, chronic, and life-threatening disorders. Plasma products play a crucial role in medical treatment and prophylaxis. Plasma products are critical for managing bleeding emergencies, autoimmune disease, and a number of chronic conditions that include hemophilia, congenital and acquired immunodeficiencies. The increased access to medical care, new products and applications, and diagnostic advances fuel the growth of the plasma therapy market. According to the Plasma Protein Therapeutics Association, the United States was the largest contributor to the global source plasma supply in 2017. Favorable regulatory guidelines increased the availability of donors whereas efficient plasma collection infrastructure fuel the plasma therapy market worldwide.


COVID-19 Analysis


The COVID-19 pandemic outbreak, along with lockdowns imposed by governments to manage the spread of the disease, impacted several industries. The rise in infected patients impacted the management of hospitals because of its limited staff and resources in comparison to the sudden increase in the number of infected patients; this caused delayed medical procedures and surgeries. The non-emergency medical procedure was delayed, and emergency procedures that would have affected patients or could have caused loss of life if not carried out were prioritized.


The COVID-19 pandemic applied additional stress on the plasma supply. Companies, suppliers, and business owners of platelet-rich plasma (PRP) therapy products in Asian economies were affected by the sudden rise in COVID-19 patients. The middle- and low-income countries had to face challenges due to the lack of health infrastructures and regulations imposed by the governments on industries and suppliers. During pandemic, plasma therapy was proposed for the treatment because of the absence of vaccines, other specific drugs, and treatment.


Market Dynamics


Drivers




  • Rise in COVID-19 cases around the globe

    • COVID-19 is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. It is a new disease with a lack of knowledge and effective treatments. The plasma of a person who has recovered from COVID-19 is used as a potential cure for the virus. The plasma is the acellular component of blood that contains antibodies and the antibodies that precisely recognize SARS-CoV-2. When the plasma was transfused into patients infected with SARS-CoV-2, it showed a positive response against the virus. This boosted plasma therapy and its use in the treatment of the inclining cases in the world.





  • Rising awareness among the population regarding the diseases and potential treatment options


Market Restraints




  • High cost of plasma therapy

    • The high cost of plasma therapy is expected to hinder the market growth. The price of plasma extraction from the blood and its storage of extracted plasma are restricting the market growth. The price of therapy has restricted its use in underdeveloped and developing regions. Since the common person is not able to afford the therapy, this is one of the key factors restricting market growth.




Technology Analysis


Plasma therapy performs the replacement of deficient or missing proteins found in plasma to enable its receivers to live healthier and disorder-free lives. The therapy is used to treat various diseases such as arthritis, nutritional deficiency, bone repairing, and others. The therapy is also used for research purposes to study the effect of various viruses as well as bacteria on the body, along with bodies response to the diseases. The previously infected person's plasma contains antibodies against the diseases. These antibodies can be used for the treatment of diseases. COVID-19 outbreak witnessed plasma therapy as a potential cure for the disease. The use of plasma from the infected person for newly infected patient showed an increase in the immune response against the virus. Doctors worldwide used plasma therapy to treat highly infected people, which reduced the mortality rate effectively. 


Segment Overview


By Type



  • Pure PRP: The pure PRP segment demonstrates the largest revenue share of the global market in the year 2021, owing to the reduced or no risks in the use of pure PRP. The pure platelet-rich plasma is apreparation containing concentrated platelet growth factors with reduced red blood cells. It demonstrates good effects for the treatment of diseases in the patients. The technique is highly recommended.

  • Leukocyte-Rich PRP: The leukocyte-rich PRP is used for the treatment of osteoarthritis of the hips and knee. The leukocyte-rich PRP is a preparation with a high concentration of leukocytes. Its main function is to assist in tendon and ligament healing. The positive effects of L-PRP in several medical applications for therapeutic purposes is anticipated to register a significant growth of the leukocyte–rich PRP segment during the projected time period.

  • Pure Platelet-Rich Fibrin: It isused to promote wound healing, bone regeneration,, graft stabilization, and hemostasis. It can be defined as platelet-rich fibrin and autogenous leukocyte prepared from the blood of the patient blood.

  • Leukocyte-Rich Fibrin: It is an autologous platelet concentrate containing of a fibrin matrix enhanced with leukocytes, platelets, and an excess of growth factors and cytokines.


By Source



  • Autologous: The segment accounts for the major share of the market in 2021. High awareness of plasma therapy and its approval as a possible remedy for healing tissues and bones are surging the development of the autologous source segment in the market.

  • Allogenic: Allogeneic PRP Include 4.1-fold and 2.7- to 4.9-fold higher number of platelets and growth factors compared to whole blood, respectively


By Application



  • Dermatology: The segment is estimated to register the highest CAGR during the forecast period. This is attributed to the inclining number of patients with hair and skin-related conditions, rising beauty consciousness in the general population, and growing use of micro-needling for cosmetic procedures.

  • Orthopedic: Rising number of patients with arthritis and bone-related diseases is a major cause of rapid growth of the market segment. This involves diseases related to bones and limbs.

  • Cardiac Muscle Injury: The plasma is used to treat the cardiac muscles. Plasma is used to boost the regeneration of cardiac muscles.


By end-users



  • Hospitals & Clinics: The hospitals use plasma therapy for the treatment of diseases such as COVID-19, autoimmune disorders, cardiac-related disorders, and others.

  • Research Institutes: The research institutes utilize plasma from different patient to find the treatment for diseases that are prevalent and dangerous.


Regional Analysis


North America

  • High awareness and well-developed healthcare infrastructure in the region is driving the North American plasma therapy market


North America held the largest plasma therapy market share in 2020, owing to the availability of leading platelet-rich plasma therapy product manufacturers, active participation of research and academic institutes to conduct advanced research and development activities, rising awareness toward benefits of platelet-rich plasma therapies, and assistance from regulatory authorities and government to encourage the use of PRP for medical applications. The well-developed healthcare infrastructure in the region, along with the availability of highly skilled professionals is further contributing to the market growth.


Asia-Pacific



  • Increasing participation of government bodies for the use of plasma therapy in the region is fueling the Asia-Pacific plasma therapy market


The high population in the region and the constant emergence of chronic diseases are the major factors boosting the market growth in the region. The developing healthcare facilities and active government participation for the improvement of public health is providing huge opportunities for the market. The outbreak of COVID-19 has enhanced the awareness regarding plasma therapy as is used a potential treatment. India was one of the forerunning countries to adapt the therapy. The large number of disease patients in the region is a key contributor to the regional market growth. An increase in investment by the major market players in the region is also boosting the market in Asia-Pacific.


Competitive Landscape


The global plasma therapy market has several key players. This demonstrates high competition in the market. The major market players in global plasma therapy market are BioLife Plasma Services (US), Cambryn Biologics LLC (US), Biotest (Germany), CSL Ltd. (Australia), Grifols International S.A. (Spain), Kedrion S.p.A. (Italy), LFB S.A (France), Bio Products Laboratory Ltd. (U.K.), China Biologic Products, Inc. (China), Octapharma (Switzerland), Arthrex, Inc. (US), DePuy Synthes Companies (US), Grifols S.A (Spain), Global Stem Cells Group, Inc. (US), Juventix Regenerative Medical LLC (U.S.), and Celling Biosciences, Inc. (U.S.). These industry players are coming up with various business strategies to increase their market presence. The companies invest in R&D activities to expand their product portfolio, further driving the plasma therapy market. In addition, the market players are adopting various strategies such as mergers & acquisitions, contractual agreements, new product launches, increasing investments in R&D, and partnering with other players to expand their global footprint.


List of Key Companies Covered in this Report:  



  • BioLife Plasma Services (US)

  • Cambryn Biologics LLC (US)

  • Biotest (Germany)

  • CSL Ltd. (Australia)

  • Grifols International S.A. (Spain)

  • Kedrion S.p.A. (Italy)

  • LFB S.A (France)

  • Bio Products Laboratory Ltd. (U.K.)

  • China Biologic Products, Inc. (China)

  • Octapharma (Switzerland)

  • Arthrex, Inc. (US)

  • DePuy Synthes Companies (US)

  • Grifols S.A (Spain)

  • Global Stem Cells Group, Inc. (US)

  • Juventix Regenerative Medical LLC (U.S.)

  • Celling Biosciences, Inc. (U.S.)


Recent Developments



  • In October 2021, BioLife Plasma Services (US) opened its new plasma center in Worcester to meet the growing demand for plasma-related therapies.

  • In August 2021, Biotest AG (Germany) Opened its sixth plasma collection center in the Czech Republic. The expansion of new centers to ensure long-term plasma supply.

  • In June 2020, CSL Behring (Australia) entered into an agreement to acquire Vitaeris Inc., a clinical-stage biotechnology company for the phase III development of canakinumab, an anti-interleukin-6 (IL-6) monoclonal antibody (MAB).

  • In April 2020, China Biologic Products Holdings, Inc. (China), a fully integrated plasma-based biopharmaceutical company merged with CBPO Group Limited to strengthen it's offerings.


Report Overview


The study covers the existing short-term and long-term market effects, as well as helping decision-makers to draught short-term and long-term plans for businesses by region. The report covers major regions in North America, Europe, Asia-Pacific, and the Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter's Five Forces, value chain, and impact of COVID-19 on the market.


Scope of the Report & Segmentation


By Type



  • Pure PRP

  • Leukocyte-Rich PRP

  • Pure Platelet-Rich Fibrin

  • Leukocyte-Rich Fibrin


By Source



  • Autologous

  • Allogenic


By Application



  • Orthopedic

  • Dermatology

  • Cardiac Muscle Injury

  • Dental

  • Nerve Injury


By End-users



  • Hospitals & Clinics

  • Research Institutes



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 895.45 Million
  CAGR   ~13.8%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Types, Source, and Application
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World
  Key Vendors   • BioLife Plasma Services (US) • Cambryn Biologics LLC (US) • Biotest (Germany) • CSL Ltd. (Australia) • Grifols International S.A. (Spain) • Kedrion S.p.A. (Italy) • LFB S.A (France) • Bio Products Laboratory Ltd. (U.K.) • China Biologic Products, Inc. (China) • Octapharma (Switzerland) • Arthrex, Inc. (US) • DePuy Synthes Companies (US) • Grifols S.A (Spain) • Global Stem Cells Group, Inc. (US) • Juventix Regenerative Medical LLC (U.S.) • Celling Biosciences, Inc. (U.S.)
  Key Market Opportunities   The emergence of new products in plasma therapy boost the market growth
  Key Market Drivers   • Rise in COVID-19 cases around the globe • Rising awareness among the population regarding the diseases and potential treatment options


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The plasma therapy market is projected to reach USD 895.45 million by 2030 at a CAGR of 13.8%.

BioLife Plasma Services (US), Cambryn Biologics LLC (US), Biotest (Germany), CSL Ltd. (Australia), Grifols International S.A. (Spain), Kedrion S.p.A. (Italy), LFB S.A (France), Bio Products Laboratory Ltd. (U.K.), China Biologic Products, Inc. (China), Octapharma (Switzerland), Arthrex, Inc. (US), DePuy Synthes Companies (US), Grifols S.A (Spain), Global Stem Cells Group, Inc. (US), Juventix Regenerative Medical LLC (US), and Celling Biosciences, Inc. (US) are the key players in the market of plasma therapy

North America is predicted to lead the market of plasma therapy

Rising awareness among the population regarding the diseases and potential treatment options are the major market driver of plasma therapy

High cost of plasma therapy may limit the market growth of plasma therapy